Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission

Journal of Infectious Diseases

Volumn 208, Issue 4, 2013, Pages 662-671

  Vardhanabhuti, Saran ^a   Acosta, Edward P ^b   Ribaudo, Heather J ^a   Severe, Patrice ^f   Lalloo, Umesh ^g   Kumarasamy, Nagalingeshwaran ^h   Taulo, Frank ^j   Kabanda, Joseph ^k   Oneko, Olola ^l   Ive, Prudence ^m   Sambarey, Pradeep ⁱ   Chan, Ellen S ^a   Hitti, Jane ^c   Hong, Francis ^d   McMahon, Deborah ^d   Haas, David W ^e,n  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^g UNIVERSITY OF KWAZULU NATAL   (South Africa)

^h VHS Medical Centre India   (India)

ⁱ B J MEDICAL COLLEGE   (India)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^l KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^m UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁿ Departments of Medicine Pharmacology Pathology Microbiology Immunology Vanderbilt Health   (United States)

more..

Author keywords

CYP2B6; Nevirapine; Pharmacogenetics; Pharmacokinetics; Pregnancy

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EMTRICITABINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; TENOFOVIR;

ABCB1 GENE; ADULT; ARTICLE; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYP2B6 GENE; CYP2C19 GENE; CYP3A4 GENE; CYP3A5 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; FEMALE; FETOMATERNAL TRANSFUSION; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; INFECTION PREVENTION; LABOR ONSET; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; NR1I2 GENE; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; SINGLE DRUG DOSE; VIRUS RESISTANCE; VIRUS TRANSMISSION;

CYP2B6; NEVIRAPINE; PHARMACOGENETICS; PHARMACOKINETICS; PREGNANCY;

ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; CHEMOPREVENTION; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INHIBITORY CONCENTRATION 50; MALE; METABOLIC CLEARANCE RATE; NEVIRAPINE; OXIDOREDUCTASES, N-DEMETHYLATING; PLASMA; POLYMORPHISM, GENETIC; PREGNANCY; TIME FACTORS; YOUNG ADULT;

EID: 84880963899     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit223     Document Type: Article

References (43)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of motherto- child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
2. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14:F111-5.
3. Aizire J, McConnell MS, Mudiope P, et al. Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single dose nevirapine. JAIDS 2012; 60:483-8.
4. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009; 6:e1000172.
5. Chi BH, Ellis GM, Chintu N, et al. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention. AIDS Res Hum Retroviruses 2009; 25:1099-106.
6. Arrive E, Chaix ML, Nerrienet E, et al. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS 2009; 23:825-33.
7. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-705.
8. Lallemant M, Ngo-Giang-Huong N, Jourdain G, et al. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIVresistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis 2010; 50:898-908.
9. Kunz A, Frank M, Mugenyi K, et al. Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration. J Antimicrob Chemother 2009; 63:170-7.
10. Muro E, Droste JA, Hofstede HT, Bosch M, Dolmans W, Burger DM. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. JAIDS 2005; 39:419-21.
11. Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediat Infect Dis J 2001; 20:803-5.
12. Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis 2009; 199:872-80.
13. Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27:1488-95.
14. Wang H, Tompkins LM. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current Drug Metab 2008; 9: 598-610.
15. Wen B, Chen Y, Fitch WL. Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos 2009; 37:1557-62.
16. Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, Khoo SH. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Clin Pharm Therap 2005; 78:132-42.
17. Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27:895-901.
18. Kojima K, Nagata K, Matsubara T, Yamazoe Y. Broad but distinct role of pregnane x receptor on the expression of individual cytochrome p450s in human hepatocytes. Drug Metab Pharmacokinet 2007; 22: 276-86.
19. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18:2391-400.
20. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharm Exp Therap 2003; 306:287-300.
21. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genom 2005; 15:1-5.
22. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T→C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 2008; 61:914-8.
23. Mahungu T, Smith C, Turner F, et al. Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med 2009; 10:310-7.
24. Penzak SR, Kabuye G, Mugyenyi P, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIVinfected patients in Uganda. HIV Med 2007; 8:86-91.
25. Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV- 1-infected children. AIDS 2007; 21:2191-9.
26. Ramachandran G, Ramesh K, Hemanth Kumar AK, et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother 2009; 63:841-3.
27. Uttayamakul S, Likanonsakul S, Manosuthi W, et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010; 7:8.
28. Chou M, Bertrand J, Segeral O, et al. Population pharmacokinetic- pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Ag Chemother 2010; 54:4432-9.
29. Chantarangsu S, Cressey TR, Mahasirimongkol S, et al. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J Antimicrob Chemother 2009; 64:1265-73.
30. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genom 2006; 16:191-8.
31. Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010; 202:717-22.
32. Bertrand J, Chou M, Richardson DM, et al. Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. Pharmacogenet Genom 2012; 22:868-76.
33. Holzinger ER, Grady B, Ritchie MD, et al. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols. Pharmacogenet Genom 2012; 22:858-67.
34. dbSNP - short genetic variations. http://www.ncbi.nlm.nih.gov/projects/ SNP/. Accessed 6 November 2012.
35. Acosta EP, Limoli KL, Trinh L, et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Ag Chemother 2012; 56:5938-45.
36. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci U S A 2011; 108:9202-7.
37. SeattleSNPs variation discovery resource. http://pga.gs.washington.edu/. Accessed 6 November 2012.
38. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Therap 2007; 81:557-66.
39. Ensembl. http://www.ensembl.org/index.html. Accessed 6 November 2012.
40. Lamba V, Lamba J, Yasuda K, et al. Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR Expression. J Pharmacol Exp Therap 2003; 307:906-22.
41. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11: 171-80.
42. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. JAIDS 2009; 51:522-9.
43. HIV/AIDS Programme, World Health Organization (WHO). Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach, 2010 version. Geneva: WHO, 2010. http://whqlibdoc.who.int/publications/2010/9789241599818-eng.pdf. Accessed 6 June 2013.